These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25583161)

  • 21. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
    Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
    JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes.
    Amoah V; Storey RF; Worrall AP; Goodridge K; Lovatt T; Smallwood A; Armesilla AL; Nevill AM; Cotton JM
    Platelets; 2013; 24(8):643-8. PubMed ID: 23148794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.
    Bonello L; Armero S; Ait Mokhtar O; Mancini J; Aldebert P; Saut N; Bonello N; Barragan P; Arques S; Giacomoni MP; Bonello-Burignat C; Bartholomei MN; Dignat-George F; Camoin-Jau L; Paganelli F
    J Am Coll Cardiol; 2010 Nov; 56(20):1630-6. PubMed ID: 20708365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
    Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
    Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
    Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
    Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
    J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP2C19 LOF alleles confer no risk for HTPR but higher risk for recurrent ischemic events in clopidogrel treated elderly ACS patients.
    Yang J; Wang X; Peng L; Zhang L; Li X; Liu J; Zhang Y; Xu Q; Lu C; Chen Y; Yin T
    Int J Cardiol; 2015; 189():225-7. PubMed ID: 25897911
    [No Abstract]   [Full Text] [Related]  

  • 29. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
    Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
    Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the INNOVANCE PFA P2Y assay and its association with CYP2C19 genotypes.
    Kim H; Kim Y; Koh YS; Lee HK; Chae H; Jekarl DW; Lee JM; Shin WS; Kim TH
    Platelets; 2015; 26(2):148-53. PubMed ID: 24617511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
    Palmerini T; Calabrò P; Piscione F; De Servi S; Cattaneo M; Maffeo D; Toso A; Bartorelli A; Palmieri C; De Carlo M; Capodanno D; Barozzi C; Tomasi L; Della Riva D; Mariani A; Taglieri N; Reggiani LB; Bianchi R; De Rosa R; Mariani M; Podda G; Généreux P; Stone GW; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1117-27. PubMed ID: 25240538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents.
    Choi IJ; Koh YS; Park MW; Her SH; Choi YS; Park CS; Park HJ; Kim PJ; Chung WS; Kim HS; Shin JG; Seung KB; Chang K
    Medicine (Baltimore); 2016 Jun; 95(26):e4049. PubMed ID: 27368038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes.
    Johnston LR; Larsen PD; La Flamme AC; Michel JM; Simmonds MB; Harding SA
    Int J Cardiol; 2013 Aug; 167(3):995-9. PubMed ID: 22465351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effects of cytochrome P450 2C19 genetic polymorphism on clopidogrel resistance and recent prognosis of patients with acute coronary syndrome].
    Li SN; Liu Z; Luo Y; Chen PA; Lei XM; Li GL
    Zhonghua Nei Ke Za Zhi; 2013 Nov; 52(11):961-5. PubMed ID: 24439192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Frequency of the Minor Polymorphisms in the
    Zelenskaya EM; Lifshits GI; Nikolaev KY; Donirova OS; Altayev VD; Apartsin KA; Voronina EN; Protasov KV; Sychev DA
    Genet Test Mol Biomarkers; 2020 Jun; 24(6):338-342. PubMed ID: 32392440
    [No Abstract]   [Full Text] [Related]  

  • 37. Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI.
    Zhang HZ; Kim MH; Han JY; Jeong YH
    Platelets; 2014; 25(4):285-91. PubMed ID: 23971745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests.
    Gremmel T; Kopp CW; Moertl D; Seidinger D; Koppensteiner R; Panzer S; Mannhalter C; Steiner S
    Thromb Res; 2012 May; 129(5):616-22. PubMed ID: 22154242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
    Bouman HJ; Harmsze AM; van Werkum JW; Breet NJ; Bergmeijer TO; Ten Cate H; Hackeng CM; Deneer VH; Ten Berg JM
    Heart; 2011 Aug; 97(15):1239-44. PubMed ID: 21628721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.